Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-05-16 00:00:00 ET · period of report 2024-05-14 · accession 0001601830-24-000055 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-16 | 2024-05-14 | RXRX | Borgeson Blake | Dir | S - Sale | $10.12 | -20.1K | 7.20M | -0.3% | -$202.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-05-14 | S | D | 20,054 | $10.12 | 7,198,360 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $9.74 to $10.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |